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Abstract 
Objective: To provide an up-to-date systematic review of the characteristics, 
methodology and findings of studies that have investigated the neurochemistry of 
agitation in Alzheimer’s disease (AD). 
 
Methods: Electronic databases were searched for published peer-reviewed articles 
which provided data on any neurotransmitter system in relation to agitation in AD. 
Screening of titles and abstracts and data extraction from full texts were conducted in 
duplicate.  
 
Results: Forty-five studies were included. Monoamines (serotonin, dopamine and 
noradrenaline) were most commonly investigated. A variety of methods were used to 
investigate the neurochemistry underlying agitation in AD and, although there were 
several conflicting findings, there was evidence of serotonergic deficit, relatively 
preserved dopaminergic function and compensatory overactivity of postsynaptic 
noradrenergic neurons in agitation in AD.  
 
Conclusions: Disruption of the dynamic balance between multiple neurotransmitter 
systems could impair functional neural networks involved in affective regulation and 
executive function. Differences in study design and methodology may have contributed 
to conflicting findings. Future studies that overcome these limitations (e.g. using 
standardized criteria to define agitation) and employ neuroimaging methods such as 
MRI/PET to investigate specific neural networks are needed to clarify the role of 
neurotransmitter alterations in these patients. 
 
Keywords: 
agitation; Alzheimer’s disease; neurotransmitters; monoamines 
 
1. Introduction 
Alzheimer’s disease (AD) is the most common form of dementia, accounting for up to 
60% of cases (Rizzi et al., 2014) and agitation is a common neuropsychiatric syndrome 
that affects around 50% of patients with AD (Aalten et al., 2005; Burns et al., 1990; 
Lyketsos et al., 2000). Agitation covers a broad range of symptoms including anxiety 
and irritability, motor restlessness and abnormal vocalization, as well as observable 
behaviors such as pacing, wandering, aggression, shouting and night-time disturbance 
(Howard et al., 2001). A recent consensus definition of agitation in dementia 
characterized the syndrome as observed or inferred evidence of emotional distress 
associated with excessive motor activity, verbal or physical aggression (Cummings et 
al., 2015) (Table 1). Agitation significantly reduces quality of life for patients and 
caregivers, precipitates earlier institutionalisation (Okura et al., 2011), and is associated 
with more rapid disease progression and earlier death (Peters et al., 2015). Although 
non-pharmacological approaches to the treatment of agitation have shown some 
evidence of efficacy in a care home setting (Livingston et al., 2014), patients who exhibit 
more severe agitation with higher levels of distress and associated risk often require 
additional treatment with medication. However, there are no safe and effective drug 
treatments for agitation, as the best evidence is for short-term use of atypical 
antipsychotic drugs, which have modest efficacy and are associated with significant 
harm (sedation, falls, parkinsonism, stroke) and increased mortality (Ballard and 
Howard, 2006; Schneider et al., 2006), particularly in those aged over 80 years (Howard 
et al., 2016). Citalopram, a selective serotonin reuptake inhibitor (SSRI) may also have 
a degree of efficacy but is associated with worsening cognitive function and cardiac side 
effects (Porsteinsson et al., 2014).  
  
Table 1: Consensus provisional definition of agitation in cognitive disorders  
A. The patient meets criteria for a cognitive impairment or dementia syndrome (e.g. 
AD, FTD, DLB, vascular dementia, other dementias, a pre-dementia cognitive 
impairment syndrome such as mild cognitive impairment or other cognitive disorder). 
B. The patient exhibits at least one of the following behaviors that are associated with 
observed or inferred evidence of emotional distress (e.g. rapid changes in mood, 
irritability, outbursts). The behavior has been persistent or frequently recurrent for a 
minimum of two weeks’ and represents a change from the patient’s usual behavior. 
(a) Excessive motor activity (examples include: pacing, rocking, gesturing, pointing 
fingers, restlessness, performing repetitious mannerisms). 
(b) Verbal aggression (e.g. yelling, speaking in an excessively loud voice, using 
profanity, screaming, shouting). 
(c) Physical aggression (e.g. grabbing, shoving, pushing, resisting, hitting others, 
kicking objects or people, scratching,biting, throwing objects, hitting self, slamming 
doors, tearing things, and destroying property). 
C. Behaviors are severe enough to produce excess disability, which in the clinician’s 
opinion is beyond that due to the cognitive impairment and including at least one of 
the following: 
(a) Significant impairment in interpersonal relationships. 
(b) Significant impairment in other aspects of social functioning. 
(c) Significant impairment in ability to perform or participate in daily living activities. 
D. While co-morbid conditions may be present, the agitation is not attributable solely 
to another psychiatric disorder, suboptimal care conditions, medical condition, or the 
physiological effects of a substance. 
 
Disruption of the dynamic balance between cholinergic and monoaminergic 
neurotransmission has been proposed to underlie the behavioral and psychological 
symptoms of dementia (BPSD) in AD (Lanari et al., 2006), and previous reviews have 
summarized the role of specific neurotransmitter systems such as serotonin (5-HT) 
(Lanctôt et al., 2001) and noradrenaline (NA) (Herrmann et al., 2004b). However, BPSD 
is a non-specific catch-all that includes a wide range of emotional responses and 
behaviors (including agitation, apathy, psychosis and depression), which are likely to 
have distinct neurochemical and neurobiological bases in the AD brain (Lanari et al., 
2006). There is increasing evidence that agitation is caused by dysfunction in specific 
neuronal networks involved in cognitive control and emotion regulation (Rosenberg et 
al., 2015), functions known to be modulated by interacting neurotransmitter systems 
(Del Arco and Mora, 2009). It is therefore logical as well as imperative that we should 
seek to understand the neurochemical basis of agitation in AD in order to effectively 
target treatment strategies.  
 
This paper aims to provide an up-to-date systematic review of the characteristics, 
methodology and findings of studies that have investigated the neurochemistry of 
agitation in AD. The recently established consensus definition of agitation (Cummings et 
al., 2015) will be used in the search criteria to optimize cross-study comparison, and the 
validity of reviewed studies will be discussed. 
 
2. Methods 
2.1 Literature search 
Online literature databases (PubMed, PsychINFO, Embase and Web of Science) were 
searched up to 19th June 2017 using the search terms (“Alzheimer’s” OR “Alzheimer” 
OR “cognitive impairment”) AND (“agitation” OR “aggression” OR “restlessness” OR 
“overactivity” OR “hyperactivity”) AND (“neurotransmitter” OR “monoamine” OR 
“serotonin” OR “dopamine” OR norepinephrine” OR “noradrenaline” OR “acetylcholine” 
OR “glutamate” OR “GABA”).  
 
2.2 Inclusion/exclusion criteria and screening 
Studies were included if they were published, peer-reviewed papers in human subjects 
diagnosed with Alzheimer’s disease, and provided data on any neurotransmitter system 
in relation to agitation. Agitated behaviors were defined as excessive motor activity, 
verbal aggression or physical aggression. Studies were excluded if they did not 
investigate agitation (as defined above) or describe any method to measure a specific 
neurotransmitter system. Case reports, poster abstracts and dissertations were also 
excluded.  
 
2.3 Data extraction 
Two authors (KL and AS) independently screened papers for inclusion based on their 
titles and abstracts, and subsequently extracted data on study characteristics, methods 
and outcome measures using a structured form. Discrepancies were resolved through 
discussion.  
 
3. Results 
3.1 Identification and characteristics of included studies 
Literature searches identified 2269 potential studies, 45 of which met inclusion criteria 
for data extraction (see Figure 1 PRISMA flow diagram). Most studies investigated one 
neurotransmitter system which was most commonly serotonin (n=17 studies), followed 
by dopamine (n= 6) and noradrenaline (n=6). Thirteen studies investigated more than 
one neurotransmitter system. The main characteristics and methodology of these 
studies are shown in Supplemental Table 1 and are summarized below.  
 
3.1.1 Study design and methodology 
Relevant studies included 26 case-control studies, 15 cross-sectional (n=10) or cohort 
studies (n=5) with no control group and 4 randomized controlled trials. Six out of the 15 
studies that did not employ an initial control group divided patients with and without 
agitation based on subsequent assessment. 
 
The majority of studies employed in vivo methods including genetic analysis (n=15), 
cerebrospinal fluid (CSF) analysis (n=6), administration of a neuroendocrine challenge 
(n=5) or measurement of plasma or platelet markers in blood (n=4). Only one 
neuroimaging study was included which used positron emission tomography (PET). 
There were 14 post-mortem studies that measured ex-vivo concentrations of 
neurotransmitter markers in the brain, of which 6 reported the cause of death and 13 
reported the mean duration of post-mortem delay.  
 
A total of 13 different behavioral scales were employed by studies to measure agitation. 
The most commonly used scale was the Neuropsychiatric Inventory (NPI) (n=12) 
followed by the Cohen-Mansfield Agitation Inventory (CMAI) (n=9) and the Behavioral 
Pathology in Alzheimer’s Disease Rating Scale (BEHAVE-AD) (n=9). Other scales that 
were used included the Neurobehavioral Rating Scale (NBRS), Alzheimer’s Disease 
Assessment Scale (ADAS), Present Behavior Examination (PBE), Brief Psychiatric 
Rating Scale (BPRS), Manchester and Oxford Universities Scale for the Psychological 
Assessment of Dementia (MOUSEPAD), retrospective Overt Aggression Scale (r-OAS) 
or modified Overt Aggression Scale (OAS-M), Gottfries-Brane-Steen (GBS) scale, 
modified Alzheimer Disease Cooperative Study—Clinical Global Impression of Change 
(mADCS-CGIC) scale and Behavior Rating scale for Dementia (BRSD). Four studies 
examined patient clinical records instead of using behavioral scales.  
 
The studies differed in how they temporally defined agitation, which is important as a 
single measurement could represent a ‘state’ marker of agitation whereas longitudinal 
measurements are more likely to detect ‘trait’ agitation, and these may be underpinned 
by different neurochemical changes (Lai et al., 2003; Minger et al., 2000). Most (n=22) 
studies conducted a single assessment of agitation, whilst others were longitudinal and 
looked either retrospectively for the occurrence of agitation during the study follow up 
period (n=18), or prospectively at several points during the study, such as before and 
after an intervention (n=4).  
 
3.1.2 Participants 
Study participants with AD had a mean age of 78 (range 51-97) years and 56% were 
female. Twelve studies reported the ethnicity of subjects (mean 58% White) and two 
were conducted in non-White Caucasian populations. Studies recruited subjects from 
the community (n=4), inpatient/care home setting (n=8) or both (n=7). Of 29 studies that 
provided the mean MMSE score of participants, 15 included subjects with moderate AD 
(MMSE 10-20) with a mean score of 15 (range 11-19.6), and 14 included subjects with 
severe AD (MMSE<10) with a mean score of 5 (range 3-8.6).  
 
Ten studies did not report on the medication status of participants, and of those that did 
only 5 studies assessed patients who were medication-free. Twenty-four studies did not 
report the psychiatric history of participants or state whether participants with specific 
psychiatric conditions were excluded from recruitment. 
 
Five studies included AD subjects who all had agitation, whereas other studies reported 
a proportion (between 5.6% to 82%, mean 48%) of AD subjects who were defined as 
agitated. The mean agitation score for these subjects was reported in 19 studies. The 
mean agitation scores using the three most commonly employed agitation scales were:  
NPI agitation/aggression subscale (mean 6, range 1.6-8.7), NPI total (31 from one 
study), CMAI verbal/physical aggression subscale (mean score 14, range 10-20.6), 
CMAI total (mean 39, range 25-63), BEHAVE-AD aggression subscale (7 from one 
study), BEHAVE-AD total (mean 10, range 9.2-14.3). Although no official severity 
threshold scores for these scales are available, the approximate severity of agitation 
indicated by these mean scores was judged by the authors to be mild to moderate. 
 
3.2 Main findings  
3.2.1 Serotonin 
There is a serotonergic deficit in AD (Whitford, 1986), and reductions in 5-HT have been 
associated with hostility, impulsivity and aggression in other neuropsychiatric patient 
populations (Duke et al., 2013). Consistent with the hypothesis that serotonergic deficits 
may be associated with agitation, three studies measured the prolactin response to d,l-
fenfluramine (an indirect central 5-HT agonist) and found that aggressive or agitated AD 
patients had higher 5-HT responsivity (Lanctôt et al., 2002a, 2002b; Mintzer et al., 
1998)), plausibly due to an overall decline in central 5-HT function with compensatory 
upregulation of remaining postsynaptic receptors. A further study reported decreased 
central 5-HT uptake together with lower platelet 3H-imipramine binding density in an 
agitated AD group (Schneider et al., 1988). A subsequent study, however, found no 
association between aggressive behaviors and platelet 5-HT concentration in AD 
(Prokšelj et al., 2014).  
 
Measurements of central 5-HT activity in humans have been predominantly based on 
CSF concentrations of 5-HIAA, the main metabolite of 5-HT (Olivier, 2004). However, 
reported CSF 5-HIAA concentration in agitated AD patients have been conflicting. 
Although one study found no correlation with agitation (Engelborghs et al., 2008), others 
have reported a positive correlation with fear-panic and anxiety scores on the Gottfries-
Brane-Steen (GBS) scale (Bråne et al., 1989), and higher CSF 5-HIAA concentrations 
in aggressive compared to both nonaggressive AD patients and healthy older people  
(Lopez et al., 1996). Similarly, low brain 5-HIAA concentration was found in the 
hippocampus (Vermeiren et al., 2014a, 2014b), but not in other cortical regions post 
mortem, in AD patients with agitation or aggression present in their final interview before 
death (‘state’ aggression) (Vermeiren et al., 2016).  
 
The serotonergic system is complex, and comprised of  multiple serotonergic receptor 
subtypes, which show region specific differences in their expression and functional  
properties (Barnes and Sharp, 1999). The evidence for the contribution of specific 
receptors in agitation or aggression appears to be strongest for the 5-HT1A and 5-HT1B 
receptors, as both have been associated with anti-aggressive properties, although 
underpinning mechanisms have not yet been fully elucidated (Olivier, 2004). 5-HT-1A 
receptors are abundant in the hippocampus, septum, neocortex and raphe nuclei, and 
are present on terminals of non-serotonergic neurons, facilitating acetylcholine (ACh), 
noradrenaline (NA) and dopamine release in the brain, whilst 5-HT1B receptors show 
high density in the pallidum and substantia nigra and can control the release of GABA, 
ACh and glutamate neurons (Filip and Bader, 2009). In line with their proposed role in 
aggression, reviewed studies have shown that 5-HT1A receptor density is higher in the 
prefrontal cortex (PFC) (Leake et al., 1993), and lower in the temporal cortex of patients 
with a history of agitation or aggression during their illness course compared to non-
agitated patients (Lai et al., 2003). The PFC has been implicated in behavioral control 
and aggression as part of a neural circuit also consisting of amygdala, anterior cingulate 
cortex (ACC) and other interconnected structures, and deficits in this circuit (e.g PFC 
lesions or hypometabolism) are associated with impulsive aggression in humans 
(Davidson et al., 2000). In addition, higher 5-HT1A receptor density in frontal cortex, 
indexed using [11C]WAY-10063 PET tracer, was associated with trait aggression in 
healthy adults (Witte et al., 2009), which the authors attributed to greater post-synaptic 
5-HT1A inhibitory activity and PFC hypofunction, leading to reduced control over limbic 
areas. 
So far no specific evidence has implicated a specific contribution of any 5-HT2 receptor 
subtype to aggression (Olivier, 2004). Similarly, findings in AD patients have been 
inconclusive: one post-mortem study reported lower cortical 5-HT2 receptor binding in 
aggressive compared to non-aggressive patients (Procter et al., 1992), while another 
showed no association between 5-HT2 binding in the frontal cortex and severity of 
agitation (Leake et al., 1993). It is unclear what role other serotonergic receptors might 
play in agitation (Olivier, 2004). One reviewed study found that patients with higher 
levels of overactivity, measured using the Present Behavioral Examination (PBE) in the 
last interview before death, had lower 5-HT6 receptor density in temporal cortex, and 
that the 5-HT6:ChAT ratio in frontal and temporal cortex correlated with aggression 
(Garcia-Alloza et al., 2004). The 5-HT6 receptor has been implicated in cognition as it 
regulates glutamatergic and cholinergic neuronal activity, but its role in agitation has not 
been established (Woolley et al., 2004), and findings from such studies need 
confirmation. No studies have investigated the 5-HT3 receptor, which has been 
implicated in anxiety disorders (Thompson and Lummis, 2007) and thus may be a 
plausible candidate for contribution to agitation in AD. Aside from these receptors, the 
serotonin transporter (5-HTT) located on serotonergic neurons also plays an important 
role in the modulation of 5-HT transmission. It has been reported that hippocampal 5-
HTT sites are preserved or upregulated in physically aggressive AD patients relative to 
controls (Lai et al., 2011).  
 
Genetic studies have also shown conflicting results. Two studies found a significant 
association between the 5-HT2A T102C polymorphism and agitation (Assal et al., 2004; 
Peters et al., 2016), whilst several others, including two performed in populations of 
non-White ethnicity, did not support this relationship (Holmes et al., 1998; Lai et al., 
2011; Lam et al., 2004; Pritchard et al., 2008; Proitsi et al., 2012). Similarly, more 
studies reported no significant association between 5-HT2C receptor polymorphisms 
and agitation (Holmes et al., 1998; Pritchard et al., 2008; Proitsi et al., 2012) than one 
that did (Peters et al., 2016). Genetic analysis of 5-HTT has also provided contradictory 
findings. A significant association between 5-HTT promoter region (5-HTTPR) 
polymorphism and aggression was found in two studies (Sukonick et al., 2001; Sweet et 
al., 2001), and between 5-HTT variable number tandem repeat (VNTR) polymorphism 
and aggression in another study (Ueki et al., 2007). These relationships, however, were 
not confirmed in several other studies (Assal et al., 2004; Ha et al., 2005; Peters et al., 
2016; Pritchard et al., 2008; Proitsi et al., 2012).  
 
Overall, there is some evidence that serotonergic dysfunction may contribute to agitated 
behaviors in AD but the exact nature or anatomical location of this dysfunction is 
unclear. This is partly due to the complexity of the serotonergic system as well as the 
inconsistent data from studies that have attempted to investigate the precise functional 
role of the serotoninergic system in this population.  
 
3.2.2 Dopamine 
There is good evidence that relative preservation of dopaminergic function in the 
context of diminished cholinergic activity could underlie psychotic symptoms in AD 
(Cummings et al., 1993), and relative dopaminergic preservation in the context of 
diminished serotonergic activity in certain brain regions has been linked to aggressive or 
impulsive behaviors in humans (Seo et al., 2008). Consistent with this hypothesis, 
reviewed studies have found a negative correlation between ChAT:DA and ChAT:D1 
ratios in temporal cortex and aggressive behavior (Minger et al., 2000), whilst DA 
concentration alone in post-mortem brain has not been associated with agitation (Bierer 
et al., 1993; Minger et al., 2000; Vermeiren et al., 2014a, 2014b). 
 
Relative preservation of dopaminergic function in agitated patients is also supported by 
studies that have examined the concentration of DA metabolites. Preserved 
concentrations of homovanillic acid (HVA) in the CSF of aggressive patients, relative to 
healthy controls (Lopez et al., 1996), and an absence of association between either 
CSF HVA or 3,4-Dihydroxyphenylacetic acid (DOPAC) and agitation (Bråne et al., 1989; 
Engelborghs et al., 2008) have been reported. Concentrations of these metabolites in 
postmortem frontal and temporal cortex was not associated with agitation (Bierer et al., 
1993; Minger et al., 2000; Vermeiren et al., 2014a) except in one study which found a 
correlation between cerebellar DOPAC:DA ratio (indicative of DA turnover) and physical 
agitation (Vermeiren et al., 2014a). Although a significant relationship was not found 
between plasma homovanillic acid (HVA) (as a measure of central DA function) and 
agitation or aggression measured pre- and post-perphenazine administration (Sweet et 
al., 1997), a trend was found to support a relative preservation of dopaminergic function 
in agitated patients.  
 
Studies that have performed genetic analyses of DA receptor polymorphisms in agitated 
AD patients have been mostly negative or inconsistent. Two studies that investigated 
the relationship between dopamine receptor D1 (DRD1) polymorphism and aggression 
did not agree on the genotype differences between asymptomatic and symptomatic 
patients, as one reported a greater prevalence of aggression in B2/B2 homozygotes 
(Sweet et al., 1998), whilst the other did not replicate this and found a stronger 
association with the B1/B2 genotype (Holmes et al., 2001). A relationship between both 
DRD1 and dopamine transporter (DAT) VNTR polymorphism and aberrant motor 
behavior has been reported (Proitsi et al., 2012), but another study found no 
relationship between DRD1 and agitation (Pritchard et al., 2009). No studies have 
reported an association between DRD2, DRD3 and DRD4 genetic polymorphisms and 
agitation (Holmes et al., 2001; Pritchard et al., 2009; Sato et al., 2009; Sweet et al., 
1998). 
 
Overall, there is evidence to support the hypothesis that dopaminergic function is 
relatively preserved in AD patients with agitation. How this system might respond and 
interact with other neurotransmitter systems in potentially causing such behaviors is still 
unclear. 
 
3.2.3 Noradrenaline 
The central noradrenergic system regulates arousal and autonomic function (Samuels 
and Szabadi, 2008), and there is evidence that hyperactivity of this system is implicated 
in agitation and aggressive behaviors in humans, including patients with AD (Herrmann 
et al., 2004b) The locus coeruleus (LC) is the major origin of NA in the CNS and early 
tau pathology in the LC may precede the hallmark appearance of tau and amyloid 
pathology in the medial temporal lobe and other cortical regions in AD (Braak et al., 
2011)). As AD progresses, the LC experiences loss of neurons and decreases in 
volume (Theofilas et al., 2016). Central NA hyperactivity could result from compensatory 
activation of remaining noradrenergic LC neurons and/or increased sensitivity of 
postsynaptic NA receptors.  
 
Several of the reviewed studies reported findings consistent with this hypothesis. Using 
the highest aggression scores recorded during the course of the patients’ illness, a post-
mortem analysis found greater loss of neurons from the rostral LC in aggressive 
compared to non-aggressive AD patients (Matthews et al., 2002). Patients with 
moderate AD (mean MMSE score 14) showed significantly greater agitation in response 
to yohimbine (an α2-adrenergic antagonist which stimulates NA activity by blocking NA-
mediated feedback inhibition of LC neurons) compared to age-matched healthy 
controls, and this correlated with higher CSF NA concentration (Peskind et al., 1998). 
However the association between CSF NA concentration and agitation did not reach 
significance in another study (Engelborghs et al., 2008).  
 
Accumulating evidence supports an inverted-U dose-response model of noradrenergic 
function which proposes that states of low stress are associated with moderate tonic LC 
neuron discharge resulting in enhanced PFC function via high-affinity α2-adrenoceptor 
activation, whereas states of high stress are associated with elevated LC discharge and 
binding to low-affinity α1-adrenoceptors resulting in impaired PFC function (Arnsten, 
2009). It is therefore plausible that the compensatory central overactivity of NA in 
response to LC neuron loss in AD could shift NA actions in the PFC to the right hand 
side of the curve, resulting in impaired attention, disinhibition and affective 
dysregulation. Consistent with this model, aggressive AD patients showed higher post-
mortem α1-adrenoceptor density and affinity in the frontal cortex (Sharp et al., 2007) 
and a blunted growth hormone response to a clonidine challenge (an α2-adrenergic 
receptor agonist) which was interpreted to reflect compensatory down-regulation of 
postsynaptic central α2-adrenoceptors in response to enhanced NA outflow (Herrmann 
et al., 2004a).  
 
In the studies reviewed, ex-vivo measurements of brain noradrenaline (NA) and 
adrenoceptor concentrations showed region-specific variation. No significant differences 
in frontal and temporal cortical NA concentration were found between aggressive and 
nonaggressive AD patients (Matthews et al., 2002; Vermeiren et al., 2016, 2014a), 
however the hippocampus had a lower NA concentration in aggressive patients 
(Vermeiren et al., 2014b). Aggressive AD subjects had higher α2, β1 and β2-
adrenoceptor levels in the cerebellum (Russo-Neustadt and Cotman, 1997) but not in 
frontal, temporal or thalamic regions (Matthews et al., 2002; Russo-Neustadt and 
Cotman, 1997).  
 
Neuropeptide Y (NPY), a neurotransmitter believed to play a role in anxiety, reduces 
noradrenergic activity (Illes and Regenold, 1990), so low NPY could enhance the 
noradrenergic contribution to agitation. Indeed, restlessness and agitated behavior in 
AD was negatively correlated with CSF levels NPY(Minthon et al., 1996) , although CSF 
NPY was also significantly correlated with duration of illness, so level of cognitive 
impairment could have been a confounding factor. 
 Overall, there is some evidence to support the hypothesis that aggressive behaviors in 
AD may result from compensatory overactivity of the NA system, secondary to neuronal 
loss in the LC with preserved or increased postsynaptic α1-adrenoceptors in a variety of 
brain regions. These regions (e.g. frontal cortex) are part of a functional network 
involved in cognitive control and emotional regulation.   
 
3.2.4 Other neurotransmitter systems: acetylcholine and GABA  
AD associated cholinergic deficits have been associated with both cognitive changes 
(Coyle et al., 1983) and BPSD (Cummings and Kaufer, 1996). Lower concentrations of 
choline acetyltransferase (ChAT) and/or acetylcholine (ACh) in temporal and frontal 
cortex were associated with aggressive behavior (Garcia-Alloza et al., 2005) and 
overactivity (Minger et al., 2000), however this has not been consistently shown (Leake 
et al., 1993; Procter et al., 1992), and more advanced disease stage (indexed by lower 
MMSE scores) in those with more marked cholinergic deficiency is a potential 
confounding factor. There was evidence that disruption of the dynamic balance between 
cholinergic activity and other neurotransmitter systems could make individuals with AD 
more susceptible to agitated behaviors. For example, the ChAT:DA and ChAT:D1 ratios 
in frontal and temporal cortex were negatively correlated with overactivity and 
aggressive behavior respectively in AD (Minger et al., 2000), and the 5-HT6:ChAT ratio 
in frontal and temporal cortex was also related to aggression (Garcia-Alloza et al., 
2004). In addition, a PET study in agitated subjects with AD found lower α4β2* nicotinic 
cholinergic receptor binding in bilateral anterior cingulate cortex (ACC) (Sultzer et al., 
2017)). Nicotinic cholinergic receptors play an important role in influencing the release 
of other neurotransmitters (Dani, 2001), thus reduced receptor availability in a region 
that modulates behavioral and emotional activation could contribute to agitation via the 
postsynaptic activity of other neurotransmitter systems. 
 
Ɣ-aminobutyric acid (GABA) is the key inhibitory neurotransmitter of the central nervous 
system and GABAergic dysfunction in AD has been proposed to contribute to BPSD 
(Lanctôt et al., 2004). There are numerous GABAA receptor subtypes, each with distinct 
properties owing to the different possible combinations of receptor subunits (Chebib and 
Johnston, 1999) and the subunit composition can affect receptor sensitivity to 
modulators such as benzodiazepines and alcohol (Rudolph and Möhler, 2004), resulting 
in either increased or decreased aggression (de Almeida et al., 2005). The two studies 
that investigated Ɣ-aminobutyric acid (GABA) included in this review found no significant 
relationship between either plasma GABA (Lanctôt et al., 2007) or cortical GABA 
concentrations (Procter et al., 1992) and aggression in AD, and did not investigate 
specific GABA receptor subtypes.  
 
Overall, apart from 5-HT, dopamine and NA, a small number of studies have implicated 
other neurotransmitter systems in agitation but these need further replication to make 
any conclusions about their possible role in agitation in AD.  
 
4. Discussion 
The reviewed studies used a variety of methods to investigate the neurochemistry 
underlying agitation in Alzheimer’s disease. Although some conclusions can be drawn 
about the potential role of specific neurotransmitter systems in agitation in AD, there 
were several conflicting findings. Here we discuss the findings and the degree to which 
some of the differences in study design and methodology may have influenced the 
consistency and validity of results and the ability to compare across studies. A number 
of recommendations for future research will also be described.  
 
Agitation in dementia has recently been defined as a syndrome characterized by 
inferred or observed evidence of emotional distress associated with at least one 
behavioral component, i.e. excessive motor activity, verbal or physical aggression 
(Cummings et al., 2015). Subjective distress is a core feature due to the consensus that 
agitated behavior is an expression of the person’s distressed emotional state, which can 
manifest as rapid changes in mood, irritability or emotional outbursts. This points to 
potential deficits in emotion regulation in agitated individuals with AD. A recent review 
(Rosenberg et al., 2015) found neuroimaging evidence of dysfunction in what could be 
termed ‘agitation circuits’ in AD subjects, comprising frontal cortex, ACC, orbitofrontal 
cortex, amygdala and insula, regions also implicated in anxiety (Grupe and Nitschke, 
2013). Neuroimaging studies of emotion regulation have revealed that subcortical 
emotion structures (especially the amygdala) are under direct regulatory control of the 
PFC (Ochsner et al., 2004), and frontal lobe or fronto-subcortical dysfunction results in 
greater disinhibition and reduced regulation of emotion and aggressive behaviors (Seo 
et al., 2008). From a neuropsychological perspective, agitation in AD could arise from a 
tendency to misinterpret/overestimate potential threats and respond with heightened 
emotional reactivity. This provides a testable hypothesis that can potentially be 
translated to human studies, although the applicability of such neuropsychological 
paradigms (which have usually been developed in healthy young adults) to patients with 
AD, especially in those with severe cognitive impairment, needs further study. In terms 
of the underlying neurobiological mechanisms, the prevalence of agitation increases 
with disease severity (Lyketsos et al., 2000), which suggests an association between 
the neurochemical processes accompanying AD disease progression and agitation.  
 
Nonetheless, the precise nature and combined effect of multiple neurochemical 
imbalances have not yet been fully elucidated. Surprisingly few studies have focused on 
brain regions proposed to be part of the ‘agitation circuit’ in AD subjects comprising 
frontal cortex, ACC, orbitofrontal cortex, amygdala and insula. Additional gaps identified 
in the research literature include the potential roles of 5-HT3 receptor and GABAA 
receptor subtypes. There were numerous conflicting findings especially within genetic 
studies, and many studies would benefit from replication. The main methodological 
issues of studies are addressed below.  
 
4.1 Limitations of reviewed studies 
Genetic analysis was the most commonly employed method within the studies that we 
reviewed, however several genetic studies recruited fewer than one hundred subjects in 
each group (Assal et al., 2004; Ha et al., 2005; Lam et al., 2004; Sukonick et al., 2001). 
These were probably underpowered to detect any significant associations as a very 
large sample size of many hundreds of subjects is usually required to detect a 
potentially small effect size of a genetic polymorphism (Hong and Park, 2012). Several 
genetic studies have also investigated the influence of a number of different 
polymorphisms relating to various neurotransmitter systems, but few reported making 
any statistical correction for multiple comparisons, which in one study made their 
apparent result non-significant (Pritchard et al., 2009). In addition, a number of in vivo 
studies measured peripheral concentrations of neurotransmitters or their metabolites to 
investigate brain neurotransmitter activity, but the specificity of these methods has not 
been established.  
 
Medication status and psychiatric history of subjects were incompletely reported, which 
could have influenced the neurochemical findings of in-vivo studies and the detection of 
agitation due to treatment-induced reduction of frequency/severity of agitated behavior. 
Although medications may target specific receptors or neurotransmitter systems, (e.g. 
cholinesterase inhibitors which enhance the cholinergic system) they may also indirectly 
modulate the neurotransmission of other systems (e.g. presynaptic nicotinic 
acetylcholine receptors are found on serotonergic, dopaminergic and noradrenergic 
neurons in the brain (Wonnacott, 1997)). Although a few studies reported post-hoc the 
absence of a statistical effect from medication or psychiatric history, it has been 
reported that chronic use of psychotropic medication could upregulate adrenergic 
receptors in frontal cortex in agitated AD patients (Sharp et al., 2007), and more widely 
it has been shown using PET that chronic antipsychotic administration can alter brain 
neurochemistry in patients with schizophrenia by increasing striatal dopamine receptors 
(Silvestri et al., 2000). 
 
The consensus definition of agitation applies to a chronic state that has been sustained 
or been frequently recurrent for at least 2 weeks (Cummings et al., 2015). Thus a single 
‘snapshot’ measurement of agitation, which was conducted in 22 studies, is likely to be 
less accurate than multiple retrospective/prospective measurements in detecting 
agitation in AD, unless it has included an assessment of behavior during the preceding 
2 weeks. This is relevant because ‘state’ versus ‘trait’ agitation may have distinct 
etiologies and be differentially regulated by neurotransmitter systems (Olivier, 2004). 
Although agitation in AD may persist for years, it can be episodic and the severity may 
fluctuate (van der Linde et al., 2016), so that studies that have assessed patients with 
mild/moderate AD may not have detected the ‘true’ final prevalence of agitation which 
has been shown to increase with worsening disease progression and severity of 
cognitive impairment (Lyketsos et al., 2000). 
 
Another factor that may have contributed to discrepancies between studies is how 
agitated behaviors have been classified. The consensus definition of agitation requires 
that there be observed or inferred evidence of emotional distress (Cummings et al., 
2015), however, none of the reviewed studies were judged to have adequately reported 
this. Aggression was the most commonly measured behavior and was investigated 
exclusively in 15 studies. While agitation may include aggressive behaviors, agitation 
can also occur without aggression (e.g. pacing, rocking, restlessness). These studies 
did not measure other agitated behaviors such as motor overactivity without aggression, 
which may have influenced their findings. Agitated behaviors were measured using a 
variety of different rating scales which are difficult to aggregate or compare across 
studies as most do not have established severity thresholds. For example, it is not 
possible to distinguish from the NPI and CMAI how the frequency or severity of 
behaviors contributed to the total score. The approximate severity of agitation indicated 
by the mean scores of the three most widely used scales (NPI, CMAI, BEHAVE-AD) 
were judged by the authors to be mild to moderate, therefore the results of this review 
may not be generalizable to individuals with severe agitation. 
 
To our knowledge, only one neuroimaging study (using PET) has investigated the 
neurochemistry of agitation in AD, perhaps due to the obvious challenges of recruiting 
and scanning this population. However, this and a previous study which used PET in 
older adults with delusions (Reeves et al., 2009) (a symptom frequently associated with 
agitation (Gilley et al., 1997)), demonstrates the feasibility of employing neuroimaging 
techniques in this population. Radiolabelled agonists or antagonists used to investigate 
the altered binding potential of specific receptor subtypes in vivo may provide additional 
support for the regional neurotransmitter deficits reported in post-mortem studies. 
Relevant radioligands are available for the dopaminergic (e.g. DRD1) and serotonergic 
(e.g. 5-HT1A) receptors, but there is a lack of relevant radioligands for the 
noradrenergic system. Although magnetic resonance imaging (MRI) cannot be used to 
visualize neuroreceptor binding, the integrity of the LC and substantia nigra (major 
sources of NA and dopamine neurons respectively) can be measured using T1- or 
magnetization transfer (MT)-weighted approaches (Nakane et al., 2008), also known as 
‘neuromelanin-sensitive’ MRI. Despite the challenges of imaging a small structure such 
as the LC, previous studies have consistently reported differences in LC signal intensity 
between patients with AD and healthy controls (Liu et al., 2017). However, more studies 
are needed to confirm the validity of using LC signal intensity as a potential biomarker of 
NA system integrity in AD.  
 
4.2 Recommendations for future studies 
To optimize the ability to aggregate and compare findings across studies, future studies 
should try to classify agitation in the same way, e.g. by using the recent consensus 
definition of agitation (Cummings et al., 2015). Further work is needed to investigate the 
neurochemistry of different components of agitation including behaviors indicative of 
emotional distress. Ideally, studies should use standard agitation scales such as the 
CMAI and NPI and report the breakdown of scores, i.e. frequency and severity 
subscores for agitated behaviors. Longitudinal assessments may be better than cross-
sectional measurements to detect agitated behaviors in mild/moderate AD, as the 
prevalence of agitation increases with AD severity.  
 
To improve the validity of findings, studies should be adequately powered and should 
try to account for medication and other psychiatric conditions, e.g. by including an age-
matched control group if possible, as these may contribute to neurotransmitter 
alterations. In post-mortem studies, the post-mortem delay, brain pH and cause of death 
are additional important parameters, as the ability to interpret postmortem studies is 
limited by agonal events as well as perimortem medication use.  
 
Further studies are needed to support and refine the hypotheses regarding the 
neurochemistry underlying agitation in AD outlined in this review. The evolution of 
neurochemical changes and the interaction of different neurotransmitter systems also 
require clarification. Neuroimaging techniques, e.g. PET-MRI technology, can be 
employed for simultaneous investigation of functional connectivity to explore specific 
neural networks, and PET neuroreceptor imaging (e.g. DRD1, 5-HT1A receptors) in 
specific brain regions including frontal cortex, ACC, orbitofrontal cortex, amygdala and 
insula, as these have been proposed to form part of an ‘agitation circuit’ within which 
PFC regulatory control of subcortical emotional centers may be dysfunctional. However, 
in the later stages of AD when agitation becomes more prevalent, the extent of neuron 
and synapse loss may make interrogation of specific brain circuits difficult to interpret 
and possibly uninformative. The use of ‘neuromelanin-sensitive’ MRI techniques to 
measure LC or substantia nigra signal intensity can potentially assess the integrity of 
the noradrenergic or dopaminergic system respectively in AD. However, the difficulty 
associated with scanning agitated individuals with AD is likely to increase with illness 
severity and degree of agitation, and severely agitated individuals may not be able to 
tolerate the procedure without sedation.  
 
Pharmacological studies of agitation in AD that use medication to target a specific 
receptor system may also provide insight into the aetiology of agitation and effective 
treatment strategies. For example, agents that improve functional serotonin 
neurotransmission such as citalopram, a selective serotonin reuptake inhibitor (SSRI), 
and carbamazepine, a sodium channel channel blocker and serotonin releasing agent, 
have been shown to be superior to placebo in treating agitation and aggression in AD 
(Porsteinsson et al., 2014; Tariot et al., 1998). Prazosin, an α1-blocker, led to greater 
improvement in AD patients with treatment-resistant agitation compared to placebo 
(Wang et al., 2009), supporting the proposed role of enhanced responsiveness to NA at 
the α1-adrenoreceptor in dementia-related agitation. Interestingly, although 
cholinesterase inhibitors are well tolerated, their main benefits for BPSD are probably 
for anxiety and apathy rather than agitation (Ballard et al., 2009). A recent clinical trial 
also implicated the cannabinoid system in AD-related agitation (Woodward et al., 
2014)). Given the evidence for the likely involvement of multiple neurotransmitter 
systems in AD-related agitation, an optimal drug therapy may be one that targets 
multiple receptors from different neurotransmitter systems. However, this may also lead 
to increased side effects and greater difficulty investigating the role of specific 
neurotransmitter systems. For example, risperidone acts as an antagonist or inverse 
agonist at multiple receptors belonging to the dopaminergic, serotonergic and 
noradrenergic systems. Memantine has shown some benefit in clinical trials and targets 
the glutaminergic system (NMDA receptor), but also acts as an antagonist to 
serotonergic (5-HT3) and cholinergic (nicotinic ACh) receptors and an agonist at 
dopaminergic (DRD2) receptors. Further clinical trials are required to determine the 
efficacy, safety and tolerability of potential pharmacological treatments, whilst 
elucidating the contribution/interaction of different neurotransmitter systems that may 
underlie agitation.  
 
4.3 Limitations of the review 
This review concentrated on neurotransmitter system changes in agitation and did not 
include studies that investigated only structural (e.g. regional brain volume) or functional 
changes (e.g. cerebral blood flow or glucose metabolism). Neither were treatment 
studies included if they did not specifically report methods to measure a 
neurotransmitter system. Although inclusion of these studies may have provided 
additional information to support the involvement of specific neurotransmitter systems 
and/or functional networks, this data would have been less specific. This review also did 
not include agitated patients who had other neuropsychiatric conditions such as other 
dementias or psychotic disorders, which may have provided further insight into the 
neurochemistry of agitation, although this would have limited the ability to cross-
compare studies. The recent (2015) consensus definition of agitation that guided our 
search criteria emerged after the publication of most reviewed studies, so it was not 
clear if all agitated behaviors were associated with behaviors indicative of emotional 
distress as this was not typically reported or measured. A quantitative statistical review 
was not the aim of this study so it cannot comment on effect sizes.  
 
5. Conclusion 
This review has found evidence to support the presence of serotonergic dysfunction, 
relatively preserved dopaminergic function and compensatory overactivity of the NA 
system in agitation in AD. These could impair functional neural networks involved in 
affective regulation and executive function. However, a causal relationship cannot be 
derived from these studies, and differences in study design and methodology may 
contribute to conflicting findings and a limited ability to cross-compare results. Future 
studies that overcome these limitations and employ standardized neuroimaging 
techniques methods such MRI and PET across the AD course are needed to clarify the 
role of neurotransmitter alterations and target appropriate drug treatments for agitation.  
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